S203: ABSCOPAL EFFECT OF RADIOTHERAPY AND NIVOLUMAB IN RELAPSED OR REFRACTORY HODGKIN LYMPHOMA: PRE-PLANNED INTERIM ANALYSIS OF THE INTERNATIONAL GHSG PHASE II AERN TRIAL by P. Bröckelmann, I. Bühnen, J. Zijlstra, A. Fossa, J. Meissner, S. Mathas, J. Rosenbrock, C. Kobe, M. Fuchs, A. Plütschow, S. Marnitz, P. Borchmann, A. Engert, C. Baues

Get full text

P1087: FAVEZELIMAB (ANTI–LAG-3) AND PEMBROLIZUMAB CO-BLOCKADE IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA WHO PROGRESSED AFTER ANTI–PD-1 THERAPY: AN OPEN-LAB... by A. F. Herrera, D. Lavie, N. A. Johnson, A. Avigdor, P. Borchmann, C. Andreadis, A. Bazargan, G. Gregory, C. Keane, T. Inna, V. Vucinic, P. L. Zinzani, H. Zhang, P. Pillai, P. Marinello, J. Timmerman

Get full text

P1184: PHASE I TRIAL OF MB-CART2019.1 IN PATIENTES WITH RELAPSED OR REFRATORY B-CELL NON-HODGKIN LYMPHOMA: 2 YEAR FOLLOW-UP REPORT by P. Borchmann, A. Lohneis, P. Gödel, H. Balke-Want, C. Schmid, F. Ayuk, S. Holtkamp, L. Hanssens, G. Zadoyan, B. Friedrichs, M. Assenmacher, I. Bürger, D. Schneider, T. Overstijns, C. Scheid, U. Holtick, S. Miltenyi, M. Hallek

Get full text

PB2115: TRIAL IN PROGRESS: A RANDOMIZED PHASE II STUDY OF MB-CART2019.1 COMPARED TO STANDARD OF CARE THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY DLBCL INELIGIBLE FOR AUTOLOGOUS ST... by P. Borchmann, P. Vandenberghe, A. Urbano, C. Haioun, F. Lemonnier, L. Griškevicius, S. Maury, S. Holtkamp, B. Friedrichs, G. Zadoyan, L. Hanssens, C. Brillant, U. Bethke, M. Assenmacher, I. Bürger, B. Philippe, T. Overstijns, U. Jäger, M. J. Kersten

Get full text

P1086: FAVEZELIMAB (ANTI–LAG-3) AND PEMBROLIZUMAB CO-BLOCKADE IN ANTI–PD-1–NAIVE PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA: AN OPEN-LABEL PHASE 1/2 STUDY... by G. Gregory, J. Timmerman, D. Lavie, P. Borchmann, A. F. Herrera, L. Minuk, V. Vucinic, P. Armand, A. Avigdor, R. Gasiorowski, Y. Herishanu, C. Keane, J. Kuruvilla, J. Palcza, P. Pillai, P. Marinello, N. A. Johnson

Get full text